Show simple item record

dc.contributor.authorWong, R
dc.contributor.authorCunningham, D
dc.contributor.authorBarbachano, Y
dc.contributor.authorSaffery, C
dc.contributor.authorValle, Juan W
dc.contributor.authorHickish, T
dc.contributor.authorMudan, S
dc.contributor.authorBrown, G
dc.contributor.authorKhan, A
dc.contributor.authorWotherspoon, A
dc.contributor.authorStrimpakos, A S
dc.contributor.authorThomas, J
dc.contributor.authorCompton, S
dc.contributor.authorChua, Y J
dc.contributor.authorChau, I
dc.date.accessioned2012-05-28T11:43:55Z
dc.date.available2012-05-28T11:43:55Z
dc.date.issued2011-09
dc.identifier.citationA multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. 2011, 22 (9):2042-8 Ann Oncolen_GB
dc.identifier.issn1569-8041
dc.identifier.pmid21285134
dc.identifier.doi10.1093/annonc/mdq714
dc.identifier.urihttp://hdl.handle.net/10541/226231
dc.description.abstractPerioperative chemotherapy improves outcome in resectable colorectal liver-only metastasis (CLM). This study aimed to evaluate perioperative CAPOX (capecitabine-oxaliplatin) plus bevacizumab in patients with poor-risk CLM not selected for upfront resection.
dc.language.isoenen
dc.rightsArchived with thanks to Annals of oncology : official journal of the European Society for Medical Oncology / ESMOen_GB
dc.subject.meshAdenocarcinoma
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAntibodies, Monoclonal, Humanized
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshChemotherapy, Adjuvant
dc.subject.meshColorectal Neoplasms
dc.subject.meshDeoxycytidine
dc.subject.meshDisease-Free Survival
dc.subject.meshFemale
dc.subject.meshFluorouracil
dc.subject.meshHumans
dc.subject.meshLiver Neoplasms
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoadjuvant Therapy
dc.subject.meshNeoplasm Staging
dc.subject.meshOrganoplatinum Compounds
dc.subject.meshPerioperative Care
dc.subject.meshRisk Factors
dc.titleA multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medicine, Royal Marsden Hospital NHS Foundation Trust, Sutton, UK.en_GB
dc.identifier.journalAnnals of Oncologyen_GB
html.description.abstractPerioperative chemotherapy improves outcome in resectable colorectal liver-only metastasis (CLM). This study aimed to evaluate perioperative CAPOX (capecitabine-oxaliplatin) plus bevacizumab in patients with poor-risk CLM not selected for upfront resection.


This item appears in the following Collection(s)

Show simple item record